Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CID-103 dose-escalation study in antibody-mediated rejection after kidney transplant
CTR20261613Phase 2Active
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CID-103 in humoral rejection, kidney allograft rejection, sponsored by CASI Pharmaceuticals, Inc.. Started Jun 2026; status: active.
02
Drugs
CID-103
03
Conditions
humoral rejectionkidney allograft rejection
Beyond the preview
Go deeper on CTR20261613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261613.